Cohesives is a French deeptech medical device company based in Dijon, Burgundy, developing a technological platform called AnCor®, the first effective adhesive for wet biological tissues. The company is developing three medical devices based on AnCor®: an internal surgical suture sealant, a skin substitute for chronic wounds, and a liquid bandage. The liquid bandage has already been licensed to a strategic player for OTC applications, with first sales expected in 2026 and initial royalty revenues in 2027.

Cohesives is composed of an experienced 7-person team led by Dr. Bertrand Perrin, a former cardiovascular surgeon, and has in-house manufacturing capabilities adapted to clinical development. AnCor® is a photopolymerizable adhesive designed for biological tissues. It anchors to the surface of tissues by penetrating them before being cured by UV light, offering unmatched adhesion properties. It is currently one of the only solutions able to effectively adhere to wet internal tissues. The technology also provides strong sealing properties, helping retain wound exudates.

Cohesives plans to develop a skin substitute for the treatment of chronic wounds in the coming years. In parallel, Medical Brands has developed a liquid bandage using AnCor® for small cuts and skin cracks. The company is currently seeking a US distributor, with a planned launch in the United States by the end of 2026 and in Europe in 2027. AnCor® is protected by 22 patents.